Heidelberg Pharma AG
XETRA:HPHA
Heidelberg Pharma AG
Capital Expenditures
Heidelberg Pharma AG
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Heidelberg Pharma AG
XETRA:HPHA
|
Capital Expenditures
-€477.7k
|
CAGR 3-Years
30%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Capital Expenditures
-€452.3m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
|
MorphoSys AG
XETRA:MOR
|
Capital Expenditures
-€2.5m
|
CAGR 3-Years
60%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
9%
|
|
|
CureVac NV
NASDAQ:CVAC
|
Capital Expenditures
-€55.2m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Capital Expenditures
-€31m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-128%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Capital Expenditures
-€33.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Heidelberg Pharma AG
Glance View
Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The company is headquartered in Ladenburg, Baden-Wuerttemberg and currently employs 89 full-time employees. The company went IPO on 2006-11-13. The firm focuses on the research and development of therapy treatments for oncology area. The company aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. The company also offers preclinical contract research services.
See Also
What is Heidelberg Pharma AG's Capital Expenditures?
Capital Expenditures
-477.7k
EUR
Based on the financial report for Nov 30, 2024, Heidelberg Pharma AG's Capital Expenditures amounts to -477.7k EUR.
What is Heidelberg Pharma AG's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
13%
Over the last year, the Capital Expenditures growth was 50%. The average annual Capital Expenditures growth rates for Heidelberg Pharma AG have been 30% over the past three years , 13% over the past five years .
You don't have any saved screeners yet